AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 42 min read$TEVA

Shields Matthew sold $532K of TEVA

Shields Matthew (EVP, Global Operations) sold 16,195 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $32.87 ($0.53M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shields Matthew
Published Jun 4, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

Because the transaction is explicitly under a 10b5-1 plan, it is less likely to reflect new, material information. The main tradable element is potential short-lived sentiment/positioning impact from insider-selling headlines.

02

Market read

Insider selling by a senior executive can move sentiment marginally, but 10b5-1 structure typically limits informational value.

03

What to watch

10b5-1 plans are pre-scheduled and often used for routine diversification/tax planning; the sale size and post-transaction holdings may not indicate a change in fundamentals.

Relevance 6/10Novelty 3/10Timing: After-hours/filing date (June 4) following the June 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for TEVA, filed June 4, detailing an executive’s open-market sale executed June 3 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA insider Matthew Shields (EVP, Global Operations) sold $532K of TEVA shares under a pre-arranged 10b5-1 plan on June 3.

Expected impact

Likely limited immediate price impact; any reaction should be muted unless accompanied by other company-specific news.

Evidence & confidence

The filing is an open-market sale by an executive, explicitly tied to a pre-arranged 10b5-1 plan, which reduces the likelihood of new, time-sensitive information.

Market effects

Sector

Minimal—this is company-specific insider activity without disclosed operational or regulatory developments.

Regional

Minimal—no stated cross-border transaction or regional catalyst.

Global

Minimal—no new global guidance, trial, or deal information is provided.

Counterpoint

What could challenge this read

Some traders may interpret repeated insider selling as a gradual confidence signal, especially if paired with other insider transactions around the same period.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; the insider sale disclosed on SEC Form 4.

  • insider
    Matthew Shields

    EVP, Global Operations; sold 16,195 shares on June 3 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min